

AACR Meeting 2023 Participation

MW011 - Pathology for Cancer Researchers

Saturday, April 15

8:00AM – 9:30 AM

Location: Room W414 - Convention Center

Lighting Up the Tumor Microenvironment: Multiplexed Spatial Analysis for Research and Clinic

Speaker: Kurt Schalper

MW012 - Utilizing AACR Project GENIE Real-world Clinico-genomic Data

Saturday, April 15

8:00AM – 9:30 AM

Location: Room W311 A-D - Convention Center

Using GENIE Data to Aid in Ancestry-Driven Recalibration of Tumor Mutational Burden And disparate Clinical Outcomes in Response to Immune Checkpoint Inhibitors

Speaker: Amin H. Nassar

DC04 - Making Your Voices Heard: AACR's Advocacy Efforts with Policy Makers- Dedicated to the Memory of Chairman John Edward Porter

Saturday, April 15

12:30PM – 1:00PM

Location: Room W314 A - Convention Center

Moderator: Roy S. Herbst

MW004- Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials

Sunday, April 16

2:35PM – 2:55 PM

Location: Valencia D - Convention Center

Standardization, prioritization and optimal use of advanced molecular studies in clinical cancer research

Presenter: Kurt Schalper

CTPL01 - Harnessing the Immune System in the Clinic

Sunday, April 16

3:00PM – 3:10PM

Location: Chapin Theater - Convention Center

Discussant: Roy S. Herbst

MCB09.04 - Signaling Pathways in Cancer Metabolism

Sunday, April 16

1:30PM – 5PM

Location: Section 10

Differential metabolic adaptations define responses of winner and loser oncogenic mutant cells in skin epidermis in vivo

Presenters: Anupama Hemalatha and Valentina Greco

TB10.02 - Tumor Heterogeneity

Sunday, April 16

1:30PM – 5PM

Location: Section 5

Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy

Presenters: J Nicholas Fisk, Stephen Gaffney, Katerina Politi, Scott Gettinger, Fernando De Miguel, Jeffrey Townsend

PS01.01 - Cancer Survivorship

Sunday, April 16

1:30PM – 5PM

Location: Section 27

Treatment with immune checkpoint inhibitors (ICIs) and the occurrence of colitis among patients with melanoma in the United States

Presenter: Xiaomei Ma

MCB09.04 - Signaling Pathways in Cancer Metabolism

Sunday, April 16

1:30PM – 5PM

Location: Section 10

Non-metabolic regulatory functions of nuclear pyruvate kinase M2 induce a MAPK mediated phenotypic switch in invasive cancers

Presenters: Andre Levchenko, Jesse Rinehart

PR01.01 - Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment

Sunday, April 16

1:30PM – 5PM

Location: Section 28

**Lung cancer screening use before & during the COVID-19 pandemic in the US:
Population-based evidence from 2019-2021**

Presenters: Hermine Poghosyan, Sayantani Sarkar, Ilana Richman

BCS02.01 - Mathematical Modeling of Tumor Growth and Treatment Response

Sunday, April 16

1:30PM – 5PM

Location: Section 31

862 / 20 - Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis of lung adenocarcinoma

Presenters: Jorge A. Alfaro-Murillo, Krishna Dasari, Jeffrey P. Townsend

MS.ET02.01 - Innovative Therapeutic Approaches

Sunday, April 16

3:07PM - 3:22PM

Location: Room W331 - Convention Center

Exploiting MGMT loss using a new class of DNA modifiers which selectively target tumor DNA and overcome therapy resistance mechanisms across multiple tumor types

Presenters: Seth Herzon and Ranjit Bindra

PO.ET02.07 - Drug Delivery Systems

Sunday, April 16

1:30PM – 5PM

Location: Section 15

2715 / 18 - Utilizing a pH sensitive peptide (pHLIP) for tumor targeted delivery of an immunogenic peptide motif

Presenters: Annali M. Yurkevicz, Yanfeng Liu, and Peter M. Glazer

PO.PS01.03 - Aging, Immune Factors, and Metabolomics

Sunday, April 16

1:30PM – 5PM

Location: Section 15

Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival

Presenter: Herbert Yu

PO.CL07.07 - Combination Immunotherapies 2

Sunday, April 16

1:30PM – 5PM

Location: Section 40

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Presenters: Sarah A. Weiss, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia Jilaveanu, and Harriet M. Kluger

PO.CL09.02 - Molecular Targeted Therapies 1

Monday, April 17

1:30PM – 5PM

Location: Section 44

In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer

Presenters: Blair McNamara, Cem Demirkiran, Stefania Bellone, Levent Mutlu, Margherita Zipponi, Miguel S. Verzos, Justin Harold, Tobias M. P. Hartwich, Gary Altwerger, Elena Ratner, Gloria Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. Schwartz, Peter Dottino, and Alessandro D. Santin

PO.CTP01.02 - Phase I Clinical Trials in Progress

Monday, April 17

1:30PM – 5PM

Location: Section 46

First-in-human study of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced/metastatic solid tumors

Presenter: Pat LoRusso

PO.CT02.01 - Phase II Clinical Trials 1

Monday, April 17

1:30PM – 5PM

Location: Section 47

Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial

Presenters: Kurt Schalper and Patricia LoRusso

DC03 - FDA Center for Tobacco Products' Priorities to Address Tobacco Use and Support the Cancer Moonshot

Monday, April 17

2:30PM – 4PM

Location: Room W330 - Convention Center

Co-Moderator: Suchitra Krishnan-Sarin

PO.TB11.04 - Metabolic Influences on the Tumor Microenvironment

Hypoxia induces down-regulation of stimulator of interferon genes (STING) that is synergized with oncometabolites

Monday, April 17

9:00AM – 12:30PM

Location: Section 3

Presenters: Yuhong Lu, Annali Yurkevicz, Yanfeng Liu, Jonathan Dow, Peter M. Glazer

PO.ET05.01 - Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy

Concomitant inhibition of Aurora kinase A and WEE1 kinases results in synergistic tumor control and heightens DNA replication stress in head and neck and lung carcinomas

Monday, April 17

9:00AM – 12:30PM

Location: Section 15

Presenters: Jong Woo Lee, Sundong Kim, Sebastian Cruz-Gomez, Jackie Shi, and Barbara Burtness

PO.ET05.01 - Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy

Mechanistic studies of KL-50, a novel imidazotetrazine for the treatment of MGMT-/MMR- gliomas and glioblastoma

Monday, April 17

9:00AM – 12:30PM

Location: Section 15

Presenters: Eric D. Huseman, Anna Lo, Olga Fedorova, Kingson Lin, Susan Gueble, Ranjini Sundaram, Anna M. Pyle, Ranjit S. Bindra, and Seth Herzon

PO.ET09.03 - Novel Antitumor Agents 3

Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of Enzalutamide-resistant prostate cancer

Monday, April 17

9:00AM – 12:30PM

Location: Section 17

Presenter: Ranjit Bindra

PO.IM01.08 - Immunomodulatory Agents and Interventions 1

Durable eradication of tumors by single injections of a pHLIP-STING agonist

Monday, April 17

9:00AM – 12:30PM

Location: Section 23

Presenter: Donald Engelman

PO.IM01.09 - Immunomodulatory Agents and Interventions 2

TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation

Monday, April 17

9:00AM – 12:30PM

Location: Section 24

Presenters: Kurt A. Schalper and Angelo Porciuncula

PO.CL07.09 - Immune Response to Therapies

Single cell RNA sequencing defines dynamic immune cell subsets in serial colon and peripheral blood samples in a patient with checkpoint inhibitor-induced colitis

Monday, April 17

9:00AM – 12:30PM

Location: Section 43

Presenters: Jacqueline E. Mann, Liliana Lucca, Matthew Austin, Ross D. Merkin, Lilach Aizenbud, Kevan Herold, Marie Robert, and Harriet M. Kluger

PO.TB11.08 - Tumor-Host Interactions and Disease Progression

Clinical significance of PARP7 (TIPARP) gene copy number alterations in human non-small cell and head & neck carcinomas

Monday, April 17

1:00PM – 5:00PM

Location: Section 6

Presenters: Viviana A. Ahumada, and Kurt Schalper

SS04 - AACR-ASCO Joint Session: Myeloid-targeted Agents for Solid Tumors

Welcome and introductory remarks from the ASCO President

Monday, April 17

4:48PM – 4:50PM

Location: Room W315 - Convention Center

Speaker: Eric Winer

SY31 - Radiation Therapy, DNA Damage, and Immune Response

Monday, April 17

12:30PM – 2:00 PM

Location: Room W304 A-D - Convention Center

Exploiting DNA Damage Response Pathways to Stimulate Immunotherapy Response in Glioma

Speaker: Ranjit S. Bindra

PO.CTP01.01 - Phase I and First-in-Human Clinical Trials in Progress

First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors

Tuesday, April 18

1:30PM – 5:00 PM

Location: Section 46

Presenter: Patricia LoRusso

SY25 - The Connection between Autoimmunity and Immunotherapy in Cancer

Tuesday, April 18

10:15 AM – 11:45 AM

Location: Valencia BC - Convention Center

Preclinical Advances in Irreversible Diagnosis and Management

Speaker: Kevan Herold

SY34 - Future of Phase I Clinical Trials

Tuesday, April 18

12:30PM – 2:00 PM

Location: Room W311 E-H - Convention Center

Conjugates: Selection, Drug Resistance, And Combinations

Speaker: Patricia M. LoRusso

CTPL04 - Novel Biomarker-driven Molecularly Targeted Therapy Trials

Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations

Tuesday, April 18

11:15AM – 11:30 AM

Location: Chapin Theater - Convention Center

Presenter: Michael Cecchini

PO.PS01.02 - GWAS/Post-GWAS

Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review

Tuesday, April 18

1:30PM – 5:00 PM

Location: Section 26

Presenter: Amy Justice

PO.CL01.13 - Spatial Proteomics and Transcriptomics 2

Tumor immune microenvironment & genomic features of non-small cell lung carcinomas in patients with HIV (PWH)

Wednesday, April 19

9:00AM – 12:30 PM

Location: Section 43

Presenters: Shruti Desai, Kishu Ranjan, Syim Salahuddin, Ramsey Yusuf, Jianlei Gu, Daiwei Tang, Yong Kong, Barani Kumar Rajendran, Hongyu Zhao, Yuval Kluger, Sarah Goldberg, Brinda Emu, and Kurt Schalper

SY09 - Cancer Ecosystem: Malignant Cells, Microenvironment and More
Wednesday, April 19

10:15AM – 11:45 AM

Location: Valencia A - Convention Center

Autologous Humanized PDX Modeling for Immuno-Oncology Recapitulates the Human Tumor Microenvironment

Speaker: Michael Chiorazzi